CHUQ Research Center/CHUL, Quebec, Quebec, Canada.
Thromb Haemost. 2012 Oct;108(4):605-15. doi: 10.1160/TH12-03-0153. Epub 2012 Jul 26.
Bleeding and thrombotic disorders are major complications affecting patients with chronic kidney disease (CKD). Exposure of circulating platelets to uraemic toxins and contact with artificial surfaces during dialysis induce platelet abnormalities and alter the platelet proteome. We hypothesised that these changes may be subsequent to changes in the composition and/or regulation of the platelet transcriptome. In this study, we investigated the circulating platelets of 10 CKD patients (i.e. five chronic haemodialysis patients and five stage 4 CKD uraemic patients) and five age- and sex-matched healthy subjects. We observed an alteration of the platelet messenger RNA (mRNA) and microRNA transcriptome in CKD patients. Impaired in uraemic platelets, the levels of some mRNAs and of most microRNAs appeared to be corrected by dialysis, which is consistent with a beneficial effect of dialysis and a mRNA regulatory role of platelet microRNAs. Reduced in platelets of uraemic patients, phosphatidylcholine transfer protein (PCTP) and WD repeat-containing protein 1 (WDR1) were found to be regulated by microRNAs, the latter of which involving hsa-miR-19b, a microRNA increased in platelets of uraemic patients and involved in platelet reactivity. These results suggest that an alteration of microRNA-based mRNA regulatory mechanisms may underlie the platelet response to uremia and entail the development of platelet-related complications in CKD.
出血和血栓形成障碍是影响慢性肾脏病(CKD)患者的主要并发症。循环血小板暴露于尿毒症毒素和透析过程中与人工表面接触会导致血小板异常,并改变血小板蛋白质组。我们假设这些变化可能是血小板转录组的组成和/或调节变化的结果。在这项研究中,我们研究了 10 名 CKD 患者(即 5 名慢性血液透析患者和 5 名 4 期 CKD 尿毒症患者)和 5 名年龄和性别匹配的健康受试者的循环血小板。我们观察到 CKD 患者血小板信使 RNA(mRNA)和 microRNA 转录组发生改变。尿毒症血小板中一些 mRNA 和大多数 microRNA 的水平似乎被透析纠正,这与透析的有益作用以及血小板 microRNA 的 mRNA 调节作用一致。尿毒症患者的血小板中发现磷酯酰胆碱转移蛋白(PCTP)和 WD 重复蛋白 1(WDR1)的水平受到 microRNA 的调节,后者涉及 hsa-miR-19b,这是一种在尿毒症患者的血小板中增加的 microRNA,与血小板反应性有关。这些结果表明,基于 microRNA 的 mRNA 调节机制的改变可能是血小板对尿毒症反应的基础,并导致 CKD 中血小板相关并发症的发展。